Gruppo Tumori Testa-Collo Spedali Civili, Brescia

L'Oncologia Medica degli Spedali Civili di Brescia è una struttura clinico-scientifica-universitaria di alta specializzazione per diverse patologie tumorali.

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

#SaveTheDate: April 12th, 2024 - Consensus Conference on Larynx Preservation in Laryngeal-Hypopharyngeal Cancer.

Don't miss this incredibly chance to meet opinion leaders in #HeadandNeckCancer coming from all over the world!

📍 Registrations now open:
https://t.co/mAp8e1Dsz0

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

In this narrative review on #neoadjuvant/#induction #immunotherapy for #HNSCC:
📍 Published & ongoing trials
📍 Need for pt selection
📍 Choice of sistemic treatment
📍 Issues in radiological response assessment
📍Any space for treatment de-escalation?

👉 https://t.co/egQajKLi5g

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

Our posters for #ASCO23:
📍 #IMPEDE: safety interim analysis of ICIs in high-risk OPMDs.
📍 #IMMUNEAI: Profile of toxicities and QoL in long survival pts treated with immunotherapy - a prospective, cross-sectional study.

#Cancer #Research #Immunotherapy #Teamwork

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

How to manage severe #diarrhea in #cancerpatients?

As members of the #MASCC, Florian Scotte & Paolo Bossi discuss the importance of provider awareness of severe diarrhea and promoted an understanding of treatment options and current EBM approaches.

https://t.co/bwgN4K8oka

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

#SaveTheDate: Dec 19th, online & onsite workshop to share the first results of #ImmuneAI ↔️ an Italian, multicenter trial led in collaboration with #ATC which applies #AI to immunotherapy to foresee #QoL outcomes and #toxicities.

Want to know more? 👇
https://t.co/FV4B5iJ73i

[Make Sense Campaign @MakeSenseCmpn]

Today, we're placing the spotlight on the importance of early diagnosis of #HeadAndNeckCancer. Symptoms are easy to identify, yet 60% of patients present with locally advanced disease.

Help change this by learning the signs and symptoms: https://t.co/SKFbcuGaBW #MakeItMakeSense

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

Our #posters at #ESMO22:
📌 Long term FU of #Cemiplimab in cSCC
📌 Retrospective analysis of RM #NPC in non-endemic areas
📌 Differential espression of #PDL1 between primary and RM #HNSCC

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

#Savethedate: 27 September 2022 - Multidisciplinary Discussion on Malignant #SkullBase Cancers

Agenda:
📌 Updates on #diagnosis and #treatment
📌 Key role of a #multidisciplinaryapproach
📌 Live discussion of #realcases

Free registration here: https://t.co/jfgUEjpEAj

[JAMA Oncology @JAMAOnc]

Secondary analysis of Keynote-048 trial of pembrolizumab alone or pembro + chemo in recurrent/metastatic head & neck squamous cell carcinoma (HNSCC) shows combined positive score (CPS) for PD-L1 is associated w/overall surv but not gen prognostic factor. https://t.co/YGBO5nb5DG

[Gruppo Tumori Testa-Collo Spedali Civili, Brescia @TestaColloBS]

In un paziente anziano con #tumoretestacollo, la consulenza del geriatra può aiutare l'oncologo?

Lo studio Elderly, condotto dal prof. Bossi c/o ASST Spedali Civili e presentato all'ultimo #ESMO, sembra dirci di sì!

Full paper per saperne di più ⬇️

https://t.co/gbzpb07h0F